<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02393547</url>
  </required_header>
  <id_info>
    <org_study_id>13-007240</org_study_id>
    <nct_id>NCT02393547</nct_id>
  </id_info>
  <brief_title>Lorcaserin for Preventing Weight Gain Among Smokers</brief_title>
  <official_title>Lorcaserin for Preventing Weight Gain Among Smokers Receiving Varenicline: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be an open label clinical trial with all subjects receiving both lorcaserin and
      varenicline with a primary aim of reducing post cessation weight gain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an open label clinical trial with all subjects receiving both lorcaserin and
      varenicline. The investigators will obtain preliminary data on the efficacy of lorcaserin (10
      mg twice daily) for 12 weeks in 20 adult weight-concerned cigarette smokers with a BMI of 27
      to 40 simultaneously receiving 12 weeks of open-label varenicline and a behavioral
      intervention to assist with stopping smoking. Secondary aims will be weight, waist
      circumference, and smoking cessation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post Cessation Weight Change</measure>
    <time_frame>12 weeks</time_frame>
    <description>change in weight from baseline to week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Change in waist circumference from baseline to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Smoking Abstinence Rates</measure>
    <time_frame>12 weeks</time_frame>
    <description>prolonged smoking abstinence at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in BMI from baseline to week 12</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <condition>Weight Gain</condition>
  <arm_group>
    <arm_group_label>Varenicline + Lorcaserin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label all subjects receive both Varenicline and Lorcaserin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>All subjects receive Varenicline</description>
    <arm_group_label>Varenicline + Lorcaserin</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorcaserin</intervention_name>
    <description>All subjects receive Lorcaserin</description>
    <arm_group_label>Varenicline + Lorcaserin</arm_group_label>
    <other_name>Belviq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥18 years and ≤65 years of age;

          2. smoked ≥10 cigarettes/day for the past 6 months;

          3. BMI of 27-40 kg/m2;

          4. resides within the Olmsted County area;

          5. motivated to stop smoking;

          6. weight concerned as shown with the Weight Concern Scale;

          7. able to participate fully in all aspects of the study;

          8. understood and signed the study informed consent.

        Exclusion Criteria:

          1. current nonspecific suicidal thoughts or a lifetime history of a suicidal attempt
             (defined by the Columbia-Suicide Severity Rating Scale [C-SSRS] as a &quot;potentially
             self-injurious act committed with at least some wish to die, as a result of act.&quot;);

          2. current moderate or severe depression as assessed by a score of ≥16 on the Center for
             Epidemiologic Studies-Depression (CES-D);

          3. a lifetime history of bipolar disorder or schizophrenia;

          4. use of anti-psychotic medication within the past 30 days;

          5. use of weight-loss medications within the past 30 days or current participation in a
             program specifically designed to help with weight loss;

          6. weight fluctuations of 20 pounds or more in the past 6 months (self-report);

          7. use of any treatments for tobacco dependence within the past 30 days;

          8. use of an investigational drug within the past 30 days;

          9. recent history (past 3 months) of abuse of or dependence on a substance other than
             tobacco;

         10. current use of benzodiazepines, narcotics, anti-epileptics, or other medications known
             to interact with lorcaserin (see human subjects section);

         11. current use of triptans, monoamine oxidase inhibitors, selective serotonin reuptake
             inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs),
             dextromethorphan, tricyclic antidepressants (TCAs), bupropion, lithium, tramadol,
             tryptophan, and St. John's Wort, or any other medication known to involve the
             serotonergic neurotransmitter system (see human subjects section);

         12. uncontrolled hypertension (systolic &gt;160 mm Hg and/or diastolic &gt;100 mm Hg) documented
             on 2 separate occasions;

         13. clinically significant acute or chronic progressive or unstable neurologic, hepatic,
             renal, cardiovascular, respiratory, or metabolic disease;

         14. current use of medications known to interact with varenicline or lorcaserin;

         15. another household member or relative participating in the study;

         16. Known Diabetes;

         17. a known allergy to varenicline or lorcaserin;

         18. have taken antibiotics within the past 3 months.

         19. Women who are pregnant or lactating, or who are of childbearing potential and are
             likely to become pregnant during the medication phase but are not willing to use a
             reliable form of contraception, will also be excluded. Reliable forms of contraception
             include oral contraception, diaphragm or condom (with spermicide), injections,
             intrauterine device, surgical sterilization, and abstinence.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Hurt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hurt RT, Croghan IT, Schroeder DR, Hays JT, Choi DS, Ebbert JO. Combination Varenicline and Lorcaserin for Tobacco Dependence Treatment and Weight Gain Prevention in Overweight and Obese Smokers: A Pilot Study. Nicotine Tob Res. 2017 Aug 1;19(8):994-998. doi: 10.1093/ntr/ntw304.</citation>
    <PMID>27852796</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <results_first_submitted>March 29, 2017</results_first_submitted>
  <results_first_submitted_qc>May 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 6, 2017</results_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Ryan T. Hurt, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the community surrounding Mayo Clinic (Rochester, MN) between September 2013 and July 2014. Overweight or obese daily smokers who were interested in stopping cigarette use were recruited through the news media and local advertisements in Rochester, MN.</recruitment_details>
      <pre_assignment_details>The current study included an initial telephone screen.After the initial screen, eligible subjects were invited to come for potential enrollment. Visits prior accrual (drug dispensing) included an information meeting (screening, physician physical exam, and informed consent) and baseline visit (screening, baseline measures and drug dispensing).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Varenicline + Lorcaserin</title>
          <description>Open label all subjects receive both Varenicline and Lorcaserin
Varenicline: All subjects receive Varenicline
Lorcaserin: All subjects receive Lorcaserin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Varenicline + Lorcaserin</title>
          <description>Open label all subjects receive both Varenicline and Lorcaserin
Varenicline: All subjects receive Varenicline
Lorcaserin: All subjects receive Lorcaserin</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.7" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.3" spread="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>units on a scale -- kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.4" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102.1" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post Cessation Weight Change</title>
        <description>change in weight from baseline to week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>subjects (n=10) who met criteria for prolonged smoking abstinence at week 12</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline + Lorcaserin</title>
            <description>Open label all subjects receive both Varenicline and Lorcaserin
Varenicline: All subjects receive Varenicline
Lorcaserin: All subjects receive Lorcaserin</description>
          </group>
        </group_list>
        <measure>
          <title>Post Cessation Weight Change</title>
          <description>change in weight from baseline to week 12</description>
          <population>subjects (n=10) who met criteria for prolonged smoking abstinence at week 12</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist Circumference</title>
        <description>Change in waist circumference from baseline to week 12</description>
        <time_frame>12 Weeks</time_frame>
        <population>subjects (n=10) who met criteria for prolonged smoking abstinence at week 12</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline + Lorcaserin</title>
            <description>Open label all subjects receive both Varenicline and Lorcaserin
Varenicline: All subjects receive Varenicline
Lorcaserin: All subjects receive Lorcaserin</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference</title>
          <description>Change in waist circumference from baseline to week 12</description>
          <population>subjects (n=10) who met criteria for prolonged smoking abstinence at week 12</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Smoking Abstinence Rates</title>
        <description>prolonged smoking abstinence at week 12</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline + Lorcaserin</title>
            <description>Open label all subjects receive both Varenicline and Lorcaserin
Varenicline: All subjects receive Varenicline
Lorcaserin: All subjects receive Lorcaserin</description>
          </group>
        </group_list>
        <measure>
          <title>Smoking Abstinence Rates</title>
          <description>prolonged smoking abstinence at week 12</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BMI</title>
        <description>Change in BMI from baseline to week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>subjects (N=10) who met criteria for prolonged smoking abstinence at week 12</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline + Lorcaserin</title>
            <description>Open label all subjects receive both Varenicline and Lorcaserin
Varenicline: All subjects receive Varenicline
Lorcaserin: All subjects receive Lorcaserin</description>
          </group>
        </group_list>
        <measure>
          <title>BMI</title>
          <description>Change in BMI from baseline to week 12</description>
          <population>subjects (N=10) who met criteria for prolonged smoking abstinence at week 12</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Varenicline + Lorcaserin</title>
          <description>Open label all subjects receive both Varenicline and Lorcaserin
Varenicline: All subjects receive Varenicline
Lorcaserin: All subjects receive Lorcaserin</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <description>One serious AE of suicidal ideation was triggered by escalation of marital problems at home and adjudicated not related to the medications.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>heart burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>sleep disturbance</sub_title>
                <description>vivid dreams, sleep disturbance, insomnia</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headaches</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ryan T. Hurt, MD</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-1944</phone>
      <email>nicotineresearch@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

